CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Suramindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001266
NCT00001266Phase 2Completed
CompareCT.gov

A Phase II Trial of Leuprolide + Flutamide + Suramin in Untreated Poor Prognosis Prostate Carcinoma

National Cancer Institute (NCI)·interventional·Posted Nov 4, 1999·Updated Mar 4, 2008

In Brief

A Phase 2 clinical trial evaluating Suramin for Prostatic Neoplasm. Completed, across 1 site.

Detailed Summary

One current hypothesis as to what limits duration of initial hormone response is the rapid emergence of hormone resistant prostate carcinoma cells. Suramin has shown effectiveness as a treatment for hormonally refractory prostate carcinoma. Survival was less in patients with high rather than low circulating androgen levels. Thus, suramin might slow the emergence of hormone refractory tumor cells while combined androgen ablation may maximize the effectiveness of suramin. In this trial, we will pilot this concept.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstatic Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 1999
Enrollment StartOct 1, 1990
Study CompletionAug 1, 2003
TodayJul 2, 2026
Posted 26.7 years ago

Interventions

Suramindrug